CRISPR/Cas9-mediated PD-1 disruption enhances anti-Tumor efficacy of human chimeric antigen receptor T cells

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Rupp, Levi J ^a,b,c   Schumann, Kathrin ^b,d   Roybal, Kole T ^a,b,c   Gate, Rachel E ^b,e   Ye, Chun J ^e   Lim, Wendell A ^a,b,c   Marson, Alexander ^b,c,d,f  

^a Department of Cellular and Molecular Pharmacology ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Institute for Human Genetics   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD19 ANTIGEN; CD274 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR ANTIGEN;

ANIMAL; CRISPR CAS SYSTEM; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN; GENE TARGETING; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOPHENOTYPING; KNOCKOUT MOUSE; METABOLISM; MOUSE; NEOPLASM; PATHOLOGY; T LYMPHOCYTE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD19; ANTIGENS, NEOPLASM; B7-H1 ANTIGEN; BIOMARKERS; CELL LINE, TUMOR; CRISPR-CAS SYSTEMS; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GENE TARGETING; HUMANS; IMMUNOPHENOTYPING; MICE; MICE, KNOCKOUT; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 85018998407     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-00462-8     Document Type: Article

References (37)

1. Maus, M. V. et al. Adoptive Immunotherapy for Cancer or Viruses. Annu Rev Immunol 32, 189-225 (2014).
2. Mandal, P. K. et al. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell 15, 643-652 (2014).
3. Schumann, K. et al. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci USA 112, 10437-10442 (2015).
4. Hendel, A. et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol 33, 985-989 (2015).
5. Wu, C.-Y., Rupp, L. J., Roybal, K. T. & Lim, W. A. Synthetic biology approaches to engineer T cells. Current opinion in immunology 35, 123-130 (2015).
6. Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62-68 (2015).
7. Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74-80 (2015).
8. Bryan, L. J. & Gordon, L. I. Releasing the Brake on the Immune System: The PD-1 Strategy for Hematologic Malignancies. Oncology 29, 431-439 (2015).
9. Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682-687 (2005).
10. Pauken, K. E. & Wherry, E. J. Overcoming T cell exhaustion in infection and cancer. Trends Immunol 36, 265-276 (2015).
11. Patel, S. P. & Kurzrock, R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Molecular Cancer Therapeutics 14, 847-856 (2015).
12. Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkins lymphoma. N. Engl. J. Med. 372, 311-319 (2015).
13. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
14. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
15. John, L. B. et al. Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells. Clinical Cancer Research 19, 5636-5646 (2013).
16. Fedorov, V. D., Themeli, M. & Sadelain, M. PD-1-And CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-Target immunotherapy responses. Sci Transl Med 5, 215ra172-215ra172 (2013).
17. Poirot, L. et al. Multiplex Genome-Edited T-cell Manufacturing Platform for Off-The-Shelf Adoptive T-cell Immunotherapies. Cancer Research 75, 3853-3864 (2015).
18. Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26, 677-704 (2008).
19. Wu, C.-Y., Roybal, K. T., Puchner, E. M., Onuffer, J. & Lim, W. A. Remote control of therapeutic T cells through a small moleculegated chimeric receptor. Science 350, aab4077-1: 4077-10 (2015).
20. Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517 (2014).
21. Chang, C.-H. et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell 162, 1229-1241 (2015).
22. Kleffel, S. et al. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell 162, 1242-1256 (2015).
23. Parry, R. V. et al. CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms. Mol Cell Biol 25, 9543-9553 (2005).
24. Guedan, S. et al. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood 124, 1070-1080 (2014).
25. Carpenito, C. et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA 106, 3360-3365 (2009).
26. Zhao, Z. et al. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. Cancer Cell 28, 415-428 (2015).
27. Amarnath, S. et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med 3, 111ra120-111ra120 (2011).
28. Odorizzi, P. M., Pauken, K. E., Paley, M. A., Sharpe, A. & Wherry, E. J. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. Journal of Experimental Medicine 212, 1125-1137 (2015).
29. Singh, N., Perazzelli, J., Grupp, S. A. & Barrett, D. M. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci Transl Med 8, 320ra3-320ra3 (2016).
30. Torikai, H. et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimericantigen-receptor and eliminate expression of endogenous TCR. Blood 119, 5697-5705 (2012).
31. Berdien, B., Mock, U., Atanackovic, D. & Fehse, B. TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer. Gene Therapy 21, 539-548 (2014).
32. Wang, H. et al. One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering. Cell 153, 910-918 (2013).
33. Tsai, S. Q. et al. GUIDE-seq enables genome-wide profiling of off-Target cleavage by CRISPR-Cas nucleases. Nat Biotechnol 33, 187-197 (2015).
34. Slaymaker, I. M. et al. Rationally engineered Cas9 nucleases with improved specificity. Science 351, 84-88 (2016).
35. Kleinstiver, B. P. et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-Target effects. Nature 529, 490-495 (2016).
36. Parnas, O. et al. A Genome-wide CRISPR Screen in Primary Immune Cells to Dissect Regulatory Networks. Cell 162, 675-686 (2015).
37. Anders, C. & Jinek, M. In vitro enzymology of Cas9. Methods in Enzymology 546, 1-20 (2014).